Kompleksowa klasyfikacja zaburzeń skroniowo-żuchwowoych 

1.  Ekberg E, Nilner M: Treatment outcome of appliance therapy in temporomandibular disorder patients with myofascial pain aft er 6 and 12 months, Acta Odontol Scand 62(6):343–349, 2004.

2. Wilkinson T, Hansson TL, McNeill C, Marcel T: A comparison of the success of 24-hour occlusal splint therapy versus nocturnal occlusal splint therapy in reducing craniomandibular disorders, J Craniomandib 

3.  

    Singh PK, Alvi HA, Singh BP, et al.: Evaluation of various treatment modalities in sleep bruxism, J Prosthet Dent 114(3):426-431, 2015.
4. Kuttila M, Le Bell Y, Savolainen-Niemi E, et al: Efficiency of occlusal appliance therapy in secondary otalgia and temporomandibular disorders, Acta Odontol Scand 60(4):248–254, 2002.
5.  Ekberg E, Nilner MA: 6- and 12-month follow-up of appliance therapy in TMD patients: a follow-up of a controlled trial, Int J Prosthodont 15(6):564–570, 2002.
6. Ekberg E, Vallon D, Nilner M: The efficacy of appliance therapy in patients with temporomandibular disorders of mainly myogenous origin. A randomized, controlled, short-term trial, J Orofac Pain 17(2):133–139, 2003.
7. Forssell H, Kalso E, Koskela P, et al: Occlusal treatments in temporomandibular disorders: a qualitative systematic review of randomized controlled trials, Pain 83(3):549–560, 1999.
8.  Al-Ani MZ, Davies SJ, Gray RJ, Sloan P, Glenny Am: Stabilisation splint therapy for temporomandibular pain dysfunction syndrome, Cochrane Database Syst Rev (1):CD002778, 2004.
9.  Sjoholm T, Kauko T, Kemppainen P, Rauhala E: Long-term use of occlusal appliance has impact on sleep structure, J Oral Rehabil 41(11):795-800, 2014.
10.  Wassell RW, Adams N, Kelly PJ: Treatment of temporomandibular disorders by stabilising splints in general dental practice: results after initial treatment, Br Dent J 197(1):35–41, 2004. discussion 31; quiz 50–51.
11.  VanHelder WP: Medical treatment of muscle soreness, Can J Sport Sci 17(1):74, 1992.
12.  Cairns BE: Pathophysiology of TMD pain: basic mechanisms and their implications for pharmacotherapy, J Oral Rehabil 37(6):391– 410, 2010.
13.  Hersh EV, Balasubramaniam R, Pinto A: Pharmacologic management of temporomandibular disorders, Oral Maxillofac Surg Clin North Am 20(2):197–210, 2008. vi.
14.  Kakulas BA, Adams RD: Diseases of Muscle, ed 4, Philadelphia, PA, 1985, Harper and Row Publishers.
15.  Mense S: Nociception from skeletal muscle in relation to clinical muscle pain, Pain 54(3):241–289, 1993.
16.  Simons DG, Travell JG, Simons LS: Travell & Simons’ Myofascial Pain and Dysfunction: The Trigger Point Manual, ed 2, 178–186, Baltimore, 1999, Williams & Wilkins.
17.  Simons DG, Travell JG, Simons LS: Travell & Simons’ myofascial pain and dysfunction: a trigger point manual, ed 2, Baltimore, MD, 1999, Williams & Wilkins.
18.  Sarlani E, Grace EG, Reynolds MA, Greenspan JD: Evidence for up-regulated central nociceptive processing in patients with masticatory myofascial pain, J Orofac Pain 18(1):41–55, 2004.
19.  Simons DG, Travell JG, Simons LS: Travell & Simons’ Myofascial Pain and Dysfunction: The Trigger Point Manual, ed 2, 226–227, Baltimore, 1999, Williams & Wilkins.
20.  Younger JW, Shen YF, Goddard G, Mackey SC: Chronic myofascial temporomandibular pain is associated with neural abnormalities in the trigeminal and limbic systems, Pain 149(2):222–228, 2010.
21.  Simons DG, Travell JG, Simons LS: Travell & Simons’ Myofascial Pain and Dysfunction: The Trigger Point Manual, ed 2, 186–220, Baltimore, 1999, Williams & Wilkins.
22.  Moldofsky H, Scarisbrick P: Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation, Psychosom Med 38(1):35–44, 1976.
23.  Deleted in Review
24.  Deleted in Review
25.  Deleted in Review.
26.  Jaeger B, Reeves JL: Quantification of changes in myofascial trigger point sensitivity with the pressure algometer following passive stretch, Pain 27(2):203–210, 1986.
27.  Vazquez-Delgado E, Cascos-Romero J, Gay-Escoda C: Myofascial pain associated to trigger points: a literature review. Part 2: differential diagnosis and treatment, Med Oral Patol Oral Cir Bucal 15(4):e639–e643, 2010.
28.  Deleted in Review.
29.  Hains G, Descarreaux M, Hains F: Chronic shoulder pain of myofascial origin: a randomized clinical trial using ischemic compression therapy, J Manip Physiol Th er 33(5):362–369, 2010.
30.  Montanez-Aguilera FJ, Valtuena-Gimeno N, Pecos-Martin D, et al: Changes in a patient with neck pain aft er application of ischemic compression as a trigger point therapy, J Back Musculoskelet Rehabil 23(2):101–104, 2010.
31. Ay S, Dogan SK, Evcik D, Baser OC: Comparison the efficacy of phonophoresis and ultrasound therapy in myofascial pain syndrome, Rheumatol Int 31(9):1203–1208, 2011.
32.  Zohn DA, Mennell JM: Musculoskeletal Pain: Diagnosis and Physical Treatment, 126–137, Boston, 1976, Little, Brown.
33.  Bonica JJ: Management of myofascial pain syndromes in general practice, JAMA 164:732–738, 1957.
34.  Kamyszek G, Ketcham R, Garcia R Jr, Radke J: Electromyographic evidence of reduced muscle activity when ULF-TENS is applied to the Vth and VIIth cranial nerves, Cranio 19(3):162–168, 2001.
35.  Simons DG, Travell JG, Simons LS: Travell & Simons’ Myofascial Pain and Dysfunction: The Trigger Point Manual, ed 2, 150–173, Baltimore, 1999, Williams & Wilkins.
36.  Pippa P, Allegra A, Cirillo L, Doni L, Rivituso C: Fibromyalgia and trigger points, Minerva, Anestesiol 60(5):281–283, 1994.
37.  Ay S, Evcik D, Tur BS: Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial, Clin Rheumatol 29(1):19–23, 2010.
38.  Carlson CR, Okeson JP, Falace DA, et al: Reduction of pain and EMG activity in the masseter region by trapezius trigger point injection, Pain 55(3):397–400, 1993.
39.  Hong CZ: Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response, Am J Phys Med Rehabil 73(4):256–263, 1994.
40.  Scicchitano J, Rounsefell B, Pilowsky I: Baseline correlates of the response to the treatment of chronic localized myofascial pain syndrome by injection of local anaesthetic, J Psychosom Res 40(1):75–85, 1996.
41.  Fine PG, Milano R, Hare BD: The effects of myofascial trigger point injections are naloxone reversible, Pain 32(1):15–20, 1988.
42.  Guttu RL, Page DG, Laskin DM: Delayed healing of muscle after injection of bupivicaine and steroid, Ann Dent 49:5–8, 1990.
43.  McCain GA: Role of physical fitness training in fibrosis/fibromyalgia syndromes, Am J Med 81(Suppl 3A):73–77, 1986.
44.  Zeno E, Griffin J, Boyd C, Oladechin A, Kasser R: The effects of a home exercise program on pain and perceived dysfunction in a woman with TMD: a case study, Cranio 19(4):279–288, 2001.
45.  Okeson JP: Bell’s oral and facial pains, ed 7, Chicago, IL, 2014, Quintessence Publishing Co, Inc, pp 71-91.
46.  Bowsher D: Neurogenic pain syndromes and their management, Br Med Bull 47(3):644–666, 1991.
47.  LaMotte RH, Shain CN, Simone DA, Tsai EF: Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms, J Neurophysiol 66(1):190–211, 1991.
48.  Sessle BJ: Th e neural basis of temporomandibular joint and masticatory muscle pain, J Orofac Pain 13(4):238–245, 1999.
49.  Simone DA, Sorkin LS, Oh U, et al: Neurogenic hyperalgesia: central neural correlates in responses of spinothalamic tract neurons, J Neurophysiol 66(1):228–246, 1991.
50.  Wong JK, Haas DA, Hu JW: Local anesthesia does not block mustard- oil-induced temporomandibular inflammation, Anesth Analg 92(4):1035–1040, 2001.
51.  Arendr-Nielsen L, Graven-Nielsen T: Muscle pain: sensory implications and interaction with motor control, Clin J Pain 24(4):291-298, 2008.
52. Carette S, McCain GA, Bell DA, Fam AG: Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study, Arthritis. Rheum 29(5):655–659, 1986.
53.  Goldenberg DL, Felson DT, Dinerman H: A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia, Arthritis Rheum 29(11):1371–1377, 1986.
54.  Croff ord LJ: Meta-analysis of antidepressants in fibromyalgia, Curr Rheumatol Rep 3(2):115, 2001.
55.  Goldenberg DL: A review of the role of tricyclic medications in the treatment of fibromyalgia syndrome, J Rheumatol Suppl 19:137–139, 1989.
56.  Reynolds WJ, Moldofsky H, Saskin P, Lue FA: The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia, J Rheumatol 18(3):452–454, 1991.
57.  Hamaty D, Valentine JL, Howard R, et al: The plasma endorphin, prostaglandin and catecholamine profi le of patients with fi brositis treated with cyclobenzaprine and placebo: a 5-month study, J Rheumatol Suppl 19:164–168, 1989.
58. Tofferi JK, Jackson JL, O’Malley PG: Treatment of fi bromyalgia with cyclobenzaprine: a meta-analysis, Arthritis Rheum 51(1):9–13, 2004.
59.  McCain GA, Scudds RA: The concept of primary fi bromyalgia (fibrositis): clinical value, relation and significance to other chronić musculoskeletal pain syndromes, Pain 33:273–287, 1988.
60. Wolfe F, Smythe HA, Yunus MB, et al: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee [see comments], Arthritis Rheum 33(2):160–172, 1990.
61. Wolfe F, Clauw DJ, Fitzcharles MA, et al: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity, Arthritis Care Res (Hoboken) 62(5):600–610, 2010.
62.  Ellingson LD, Stegner AJ, Achwabacher IJ, Koltyn KF, Cook DB: Exercise strengthens central nervous system modulation of pain in fibromyalgia, Brain Sci 6(1), 2016.
63.  Rizzi M, Radovanovic D, Santus P, et al.: Influence of autonomic nervous system dysfunction in the genesis of sleep disorders infibromyalgia patients, Clin Exp Rheumatol 35 Suppl 105(3):74-80, 2017.
64.  Korszun A, Young EA, Singer K, et al: Basal circadian cortisol secretion in women with temporomandibular disorders, J Dent Res 81(4):279–283, 2002.
65. McLean SA, Williams DA, Harris RE, et al: Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia, Arthritis Rheum 52(11):3660–3669, 2005.
66.  Croff ord LJ, Demitrack MA: Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome, Rheum Dis Clin North Am 22(2):267–284, 1996.
67.  Croff ord LJ, Pillemer SR, Kalogeras KT, et al: Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia, Arthritis Rheum 37(11):1583–1592, 1994.
68.  McBeth J, Chiu YH, Silman AJ, et al: Hypothalamic-pituitary-adrenal stress axis function and the relationship with chronic widespread pain and its antecedents, Arthritis Res Th er 7(5):R992–R1000, 2005.
69.  Nishiyori M, Nagai J, Nakazawa T, Ueda H: Absence of morphine analgesia and its underlying descending serotonergic activation in an experimental mouse model of fibromyalgia, Neurosci Lett 472(3):184–187, 2010.
70. Metyas S, Rezk T, Arkefeld D, Leptich T: Autoinfl ammation and immunomodulation in inflammatory fibromyalgia syndrome- a review, Curr Rheumatol Rev 13(2):98-102, 2017.
71.  Finan PH, Zautra AJ, Davis MC, et al: Genetic influences on the dynamics of pain and affect in fibromyalgia, Health Psychol 29(2):134–142, 2010.
72.  Griep EN, Boersma JW, de Kloet ER: Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fribromyalgia syndrome [see comments], J Rheumatol 20:469–474, 1993.